Response of oral leukoplakias to the administration of vitamin A

Stich, H. F.; Hornby, A.P.; Mathew, Babu; Sankaranarayanan, Rengaswamy; Mk, Nair

doi:10.1016/0304-3835(88)90266-2

Cited by 176 publications

(76 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Complete remissions occurred in 57.1% and suppression of the development of new leukoplakia occurred in 100% of the treated group, versus 3% and 21% of the placebo group, respectively. This was confirmed by histologic and cytologic differences between biopsies taken at the beginning and the completion of the trial [18].…”

Section: Vitamin Amentioning

confidence: 62%

Advances in Chemoprevention of Head and Neck Cancer

2004

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma is a devastating disease with a poor outcome in advanced stages, accounting for approximately 3% of all malignancies, with an estimated 37,200 new cases and 11,000 deaths annually in the U.S. Second primary tumors are estimated to occur at an annual rate of 3%-10% and are significant threats to long-term survivors. Chemoprevention is an appealing strategy, and its success has been demonstrated in breast cancer and familial adenomatous polyposis. High-dose retinoids have been shown to be active against oral premalignant lesions and in prevention of second primary tumors in the head and neck. New targets include the epidermal growth factor receptor, cyclooxygenase-2, and other molecular targets. Challenges in future head and neck cancer chemoprevention investigations include achieving long-lasting efficacy with retinoids and/or new agents, and determining the optimal dose and duration of therapy while maintaining acceptable toxicities. The Oncologist 2004;9:302-311

show abstract

Section: Vitamin Amentioning

confidence: 62%

Advances in Chemoprevention of Head and Neck Cancer

2004

View full text Add to dashboard Cite

show abstract

“…Retinoids have an established effect in reversing early premalignant lesions but are associated with mucocutaneous toxicity. After Hong et al (300) showed in their 1986 randomized trial that highdose 13-cis-RA for 3 months had a 67% response rate versus 10% for placebo (P = 0.002), several other trials confirmed retinoid and vitamin A activity in oral premalignant lesions (127,301,302). Because one retinoid was not sufficient to reverse moderately and severely dysplastic lesions (which are more prone to transform than are hyperplastic lesions), a combination of IFN-a, a-tocopherol, and 13cRA was evaluated.…”

Section: Head and Neck Cancermentioning

confidence: 99%

Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward

Kelloff

Lippman

Dannenberg

et al. 2006

Clinical Cancer Research

253

196

View full text Add to dashboard Cite

This article reviews progress in chemopreventive drug development, especially data and concepts that are new since the 2002 AACR report on treatment and prevention of intraepithelial neoplasia. Molecular biomarker expressions involved in mechanisms of carcinogenesis and genetic progression models of intraepithelial neoplasia are discussed and analyzed for how they can inform mechanism-based, molecularly targeted drug development as well as risk stratification, cohort selection, and end-point selection for clinical trials.We outline the concept of augmenting the risk, mechanistic, and disease data from histopathologic intraepithelial neoplasia assessments with molecular biomarker data. Updates of work in 10 clinical target organ sites include new data on molecular progression, significant completed trials, new agents of interest, and promising directions for future clinical studies. This overview concludes with strategies for accelerating chemopreventive drug development, such as integrating the best science into chemopreventive strategies and regulatory policy, providing incentives for industry to accelerate preventive drugs, fostering multisector cooperation in sharing clinical samples and data, and creating public-private partnerships to foster new regulatory policies and public education.In most epithelial tissues, accumulating mutations (i.e., genetic progression) and loss of cellular control functions cause progressive phenotypic changes from normal histology to early precancer [intraepithelial neoplasia (IEN)] to increasingly severe IEN to superficial cancer and finally to invasive disease. This process can be relatively aggressive in some settings (e.g., in the presence of a DNA repair -deficient genotype) but generally occurs relatively slowly over years and decades. Cancer chemoprevention can be defined as the prevention of cancer or treatment of identifiable precancers (defined as histopathologic or molecular IEN). The long latency to invasive cancer is a major scientific opportunity but also an economic obstacle to showing the clinical benefit of candidate chemopreventive drugs. Therefore, an important component of chemopreventive agent development research in recent years has been to identify earlier (than cancer) end points or biomarkers that accurately predict an agent's clinical benefit or cancer incidence -reducing effect. In many cancers, IEN is an early end point. In 2002, the AACR IEN Task Force recommended focusing chemopreventive drug development on IEN because of the close association between IEN and invasive cancer and because reducing IEN burden can benefit patients by reducing cancer risk and/or the need for invasive interventions (1). The IEN Task Force proposed several practical and feasible clinical trial designs for developing new agents to treat and prevent precancer in nine cancer target organs.

show abstract

“…These authors obtained a higher number of objective responses with the administra tion of beta-carotene + vitamin A (27.5%) than with the therapy with beta-carotene only (14.8%). Many authors have reiterated the preventive and healing action of carote noids and retinoids as well as the validity of combined treatments [9][10][11]. Finally, beta-carotene is relatively cheap and the drug may therefore be administered over long periods without an excessive financial burden on the patients and on the health system.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Oral Leukoplakia with Beta-Carotene

Toma

Benso

Albanese³

et al. 1992

Oncology

View full text Add to dashboard Cite

Over the past few years, beta-carotene has progressively gained ground as a drug chosen in the treatment of oral leukoplakias, thus making it possible to reduce the use of 13-cis-retinoic acid, which was shown by many studies to be highly toxic while beta-carotene has proved to have no significant side effects and hence to be much more suitable in oral premalignancy. In 1989, a phase II study of patients showing oral leukoplakias and treated with beta-carotene (90 mg/day) was begun. A total of 23 patients (aged between 17 and 85) were included in the study and 18 (8 male and 10 female) were evaluated. Eight patients (44.4%) had objective responses (6 complete, 2 partial). Four CR and a PR appeared unexpectedly within 2-7 months after the end of the therapy. The lesions were macroscopically and histologically examined at entry; in the evaluated patients, two types of alterations were found: atypical hyperplasia (16 patients) and dysplasia (2 patients). No signs of significant toxicity were detected; only in 1 patient treatment had to be interrupted for 1 week. The results of this study show the fair efficacy of beta-carotene against oral leukoplakias, but further confirmations through controlled clinical studies are needed.

show abstract

Response of oral leukoplakias to the administration of vitamin A

Cited by 176 publications

References 19 publications

Advances in Chemoprevention of Head and Neck Cancer

Advances in Chemoprevention of Head and Neck Cancer

Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward

Treatment of Oral Leukoplakia with Beta-Carotene

Contact Info

Product

Resources

About